This is a phase I/Ib, open label study. The escalation portion will characterize the safety
and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or
melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with NPC. After the
determination of the MTD/RD for a particular treatment arm, dose expansion will further
assess safety, tolerability, PK/PD, and anti-tumor activity of each regimen at the MTD/RD.
Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer, Triple Negative Breast Cancer
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.